BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Incyclix Bio LLC

Headquarters: Durham, NC, United States
Year Founded: 2020
Status: Private
BioCentury | Aug 29, 2025
Finance

Three Hong Kong follow-ons signal warming trend: Finance Report

Akeso, Harbour BioMed and Cutia all raise cash via HKSE offerings; plus: Wugen’s nine-digit venture round, and more
BioCentury | Nov 14, 2024
Management Tracks

New CEOs at Valo, Apriori

Plus: Glasspool to lead VarmX, Novartis vet Eissa joins Cellares and updates from Mestag, Andera, Incyclix and more
BioCentury | Aug 22, 2024
Management Tracks

Dimitrios Arkilo named CMO of Actio

Plus: Coya promotes Arun Swaminathan to CEO, and updates from Tempest and Incyclix
BioCentury | Apr 18, 2024
Product Development

CDK2 inhibitors at AACR: An answer to CDK4/6 resistance?

AACR abstracts highlight CDK2 inhibition as solution to CDK4/6 resistance and route to reaching more cancer types
BioCentury | Apr 2, 2022
Emerging Company Profile

Incyclix Bio: overcoming drug resistance in breast and ovarian cancer

G1 licensee Incyclix is developing molecules selective for a target G1 was trying to avoid
Items per page:
1 - 5 of 5